Table 3.
FDA approval times
| Submission date | Approval date | Interval in days | |
|---|---|---|---|
| Axitinib | 14 April 2011 | 27 January 2012 | 288 |
| Bosutinib | 17 November 2011 | 04 September 2012 | 292 |
| Crizotinib* | 30 March 2011 | 26 August 2011 | 149 |
| Dasatinib* | 28 December 2005 | 28 June 2006 | 182 |
| Erlotinib* | 30 July 2004 | 18 November 2004 | 111 |
| Gefitinib* | 05 August 2002 | 05 May 2003 | 273 |
| Imatinib* | 27 February 2001 | 10 May 2001 | 72 |
| Lapatinib* | 13 September 2006 | 13 March 2007 | 181 |
| Nilotinib | 29 September 2006 | 29 October 2007 | 396 |
| Pazopanib | 19 December 2008 | 19 October 2009 | 304 |
| Regorafenib* | 27 April 2012 | 27 September 2012 | 153 |
| Ruxolitinib* | 03 June 2011 | 16 November 2011 | 166 |
| Sorafenib* | 08 July 2005 | 20 December 2005 | 166 |
| Sunitinib* | 11 August 2005 | 26 January 2006 | 168 |
| Vandetanib* | 07 July 2010 | 06 April 2011 | 273 |
| Vemurafenib* | 28 April 2011 | 17 August 2011 | 111 |
| Mean (n = 16) | 205.3 | ||
| Range | 72–396 | ||
| Mean for Priority review drugs (n = 12) | 167.1 | ||
| Mean for Standard review drugs (n = 4) | 320.0 | ||
*
Designated for Priority review.